Archives for News - Page 7
Biopharmaceutical company fined for misleading investors
Custom Synthesis, BOULDER, Colo. – A Colorado-based biopharmaceutical company has been penalized more than $20 million for misleading investors about the efficacy of a lung...
EU approves fifth copy of AbbVie’s $18 bln drug Humira
Custom Synthesis, Europe has approved a fifth copy of AbbVie’s $18-billion-a-year biologic drug Humira – the world’s best-selling prescription medicine – ramping up competition among...
Australian Competition and Consumer Commission clears Arrow and Apotex merger
Custom Synthesis, Strides Pharma Science Thursday said the Australian Competition and Consumer Commission (ACCC) has decided not to oppose the merger of generic pharma companies...
Apricus Biosciences merges with Seelos Therapeutics
Custom Synthesis, Apricus Biosciences will merge with Seelos Therapeutics, Inc., a privately-held biotechnology company, in an all-stock transaction, it announced on Monday, and will...
Beximco’s fifth ANDA approved in USA
Custom Synthesis, Beximco Pharmaceuticals got approval from the US Food and Drug Administration (FDA), for its Nadolol tablets, a generic equivalent of Bristol-Myers Squibb’s Corgard,...
Single bacterial strains from the human gut microbiota can serve as HDAC inhibitors
Custom Synthesis, 4D pharma showed that specific single bacterial strains from the human gut microbiota can serve as therapeutic inhibitors of the human enzyme histone...
WuXi’s API production site in china passes USFDA’s inspection
Custom Synthesis, WuXi STA Pharmaceutical’s Active Pharmaceutical Ingredient (API) production site in China, at Jinshan, Shanghai, has passed its fourth inspection from the Food...
Neurodegeneration may be tied to drainage issues in the brain
Custom Synthesis, PureTech Health’s new internal programme focused on treating central nervous system (CNS) disorders via modulation of the brain’s lymphatic system, based on the...
Positive data supports product opportunities for XF-73 in dermal infection indications
Custom Synthesis, Destiny Pharma’s first of two Phase 1 safety clinical studies of testing XF-73’s potential to cause dermal irritation, as Destiny’s lead candidate for...
UKCloud Health joins the Global Alliance for Genomics and Health
Custom Synthesis, UKCloud Health, the easy to adopt, use, and leave assured cloud services company, today announced that it has become a member of the...